An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

IF 3.1 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Medical Economics Pub Date : 2026-12-01 Epub Date: 2026-07-14 DOI:10.1080/13696998.2026.2696131

Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang, Yiran He, Keri Yang, Rhys Williams, Bijal D Shah

{"title":"An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.","authors":"Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang, Yiran He, Keri Yang, Rhys Williams, Bijal D Shah","doi":"10.1080/13696998.2026.2696131","DOIUrl":null,"url":null,"abstract":"Objective: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL).Methods: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC).Results: After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, p = .0044) and overall survival (HR, 0.46; 95% CI 0.30-0.71, p = .0005).Conclusion: These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1923-1932"},"PeriodicalIF":3.1000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2026.2696131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL).

Methods: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC).

Results: After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, p = .0044) and overall survival (HR, 0.46; 95% CI 0.30-0.71, p = .0005).

Conclusion: These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.

查看原文本刊更多论文

zanubrutinib与ibrutinib治疗复发/难治性mantle-cell淋巴瘤疗效的非锚定匹配调整间接比较。

目的：没有头对头试验比较扎鲁替尼和伊鲁替尼在复发/难治性膜细胞淋巴瘤（R/R MCL）中的疗效。方法：在系统文献综述之后，使用非锚定匹配调整间接比较（MAIC）分析来自zanubrutinib试验（n = 118）的个体患者数据和来自ibrutinib试验（n = 370）的汇总分析数据。结果：在匹配选定的协变量后，扎鲁替尼与伊鲁替尼在无进展生存方面的差异具有统计学意义(风险比[HR] = 0.63； 95%可信区间[CI] 0.46-0.87, p =。0044)和总生存率（HR, 0.46; 95% CI 0.30-0.71, p = .0005）。结论：这些MAIC分析表明，在延缓R/R MCL的疾病进展和死亡方面，扎鲁替尼可能比伊鲁替尼更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL

CiteScore

4.50

自引率

4.20%

发文量

122

期刊介绍： Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience